<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="T2" position="float">
 <label>Table 2</label>
 <caption>
  <p>Table showing the mechanism of action of DAAs[
   <xref rid="ref52" ref-type="bibr">52</xref>
   <xref rid="ref53" ref-type="bibr">53</xref>
   <xref rid="ref54" ref-type="bibr">54</xref>]
  </p>
 </caption>
 <table frame="hsides" rules="groups" width="100%">
  <thead>
   <tr>
    <th align="left" rowspan="1" colspan="1">Class of direct antiviral agents</th>
    <th align="left" rowspan="1" colspan="1">Examples</th>
    <th align="left" rowspan="1" colspan="1">Mechanism of action</th>
    <th align="left" rowspan="1" colspan="1">Comments</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left" rowspan="1" colspan="1">NS3/4A protease inhibitors</td>
    <td align="left" rowspan="1" colspan="1">1
     <sup>st</sup> generation: Telaprevir, Boceprevir 2
     <sup>nd</sup> generation: Simeprevir Next generation drugs: Glecaprevir, Grazoprevir, Paritaprevir, Voxilaprevir
    </td>
    <td align="left" rowspan="1" colspan="1">Bind to the active site of the NS3/4A protease</td>
    <td align="left" rowspan="1" colspan="1">High potency (varies by HCV genotype) Low barrier to resistance (1a&lt;1b) High potential for drug interactions Can cause rash, anemia, and raised bilirubin Later generation drugs like Glecapravir &amp; Grazoprevir are pangenotypic and are expected to have higher barriers to resistance.</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">NS5A inhibitors</td>
    <td align="left" rowspan="1" colspan="1">Daclatasvir, Elbasvir, Ledipasvir, Ombitasvir, Pibrentasvir, Velpatasvir</td>
    <td align="left" rowspan="1" colspan="1">Interact with domain 1 of the NS5A dimer, although the exact mechanism remains to be fully elucidated</td>
    <td align="left" rowspan="1" colspan="1">Moderate to high potency (consistent across HCV genotypes &amp; subtypes) High barrier to resistance (1a=1b) Low potential for drug interactions; may interact with HIV antiretrovirals (nucleoside reverse transcriptase inhibitors) and ribavirin Can cause mitochondrial toxicity</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Nucleos(t) ide analog NS5B polymerase inhibitors</td>
    <td align="left" rowspan="1" colspan="1">Sofosbuvir</td>
    <td align="left" rowspan="1" colspan="1">These are incorporated into the nascent RNA chain and result in chain termination by compromising the binding of the next incoming nucleotide</td>
    <td align="left" rowspan="1" colspan="1">Potency varies by HCV genotype Very low barrier to resistance (1a&lt;1b) Variable potential for drug interactions</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Non-nucleoside NS5B polymerase inhibitors</td>
    <td align="left" rowspan="1" colspan="1">Dasabuvir</td>
    <td align="left" rowspan="1" colspan="1">Interact with thumb 1, thumb 2, palm 1 or palm 2 domain of NS5B and inhibit polymerase activity by allosteric mechanisms of action</td>
    <td align="left" rowspan="1" colspan="1">High potency (against multiple HCV genotypes) Low barrier to resistance (1a&lt;1b) Low to moderate potential for drug interactions</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
